TPO-Mimetic Use in Children for Hemotopoietic Failure
Status:
Recruiting
Trial end date:
2022-12-03
Target enrollment:
Participant gender:
Summary
This is an open label, prospective Pilot interventional study will investigate the safety and
efficacy of Romiplostim, thrombopoietin (TPO) mimetic, in children (ages: 0 to 21 years) with
broad scope of bone marrow failure disorders including acquired and inherited conditions as a
first line of therapy along with standard of care.